

Otezla (apremilast) Prior Authorization of Benefits (PAB) Form

CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-474-3341.

1. Patient information

Patient name: _____

Patient ID#: _____

Patient DOB: _____

Date of Rx: _____

Patient phone #: _____

Patient email address: _____

2. Physician information

Prescribing physician: _____

Physician address: _____

Physician phone #: _____

Physician fax #: _____

Physician specialty: _____

Physician DEA: _____

Physician NPI #: _____

Physician email address: _____

3. Medication

4. Strength

5. Directions

6. Quantity per 30 days

Otezla (apremilast)

Specify:

7. Diagnosis: _____

8. Approval criteria: (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.)

- | | |
|--|---|
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Patient has had a diagnosis of psoriatic arthritis (PsA) and/or moderate to severe plaque psoriasis (Ps) in the last 730 days. |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Patient has had a claim for a strong CYP3A4 inducer in the last 90 days. (PLEASE NOTE: Strong CYP3A4 inducers are Actoplus Met XR, Actos, Aptiom, Atripla, bexarotene, carbamazepine, carbamazepine ER, Carbatrol ER, Dilantin, Duetact, Epitol, Equetro, Intelence, Lysodren, modafinil, Mycobutin, Mysoline, nevirapine, Orkambi, Oseni, phenobarbital, Phenytek, phenytoin, pioglitazone, Priftin, primidone, Provigil, rifabutin, Rifadin, Rifamate, rifampin, Rifater, Sustiva, Tafenlar, Targretin, Tegretol, Tegretol XR, Tracleer, Viramune, Viramune XR and Xtandi.) |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Patient has had a claim for a TNF-blocker or Interleukin-17 (IL-17) inhibitor in the last 30 days. (PLEASE NOTE: TNF-blocker or IL-17 inhibitors are Cimzia, Cosentyx, Enbrel, Humira, Simponi.) |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Patient has had a diagnosis of chronic kidney disease (stage 4 or 5) in the last 365 days. |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Requested dose is less than or equal to 30 mg per day. |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Patient has failed a 30-day treatment trial with at least one preferred agent(s) within the past 180 days. (PLEASE NOTE: The preferred agents include Enbrel and Humira.) |
| <input type="checkbox"/> Yes <input type="checkbox"/> No | Patient has a documented allergy or contraindication to preferred agents in this class. (PLEASE NOTE: The preferred agents include Enbrel and Humira.) |

☐ Yes ☐ No Does the client have a diagnosis of oral ulcers associated with Bechet's disease in the last 730 days?

For the Texas Medicaid *Preferred Drug List*, please refer to the Texas Medicaid Vendor Drug Program website at: <http://www.txvendordrug.com/formulary/preferred-drugs.shtml>.

9. Physician signature

Prescriber or authorized signature

Date

Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations and exclusions. The submitting provider certifies that the information provided is true, accurate and complete and the requested services are medically indicated and necessary to the health of the patient.

Note: Payment is subject to member eligibility. Authorization does not guarantee payment.

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.